| abstract |
The present disclosure generally relates to cell signaling inhibitors of compounds of formula (I), compositions and formulations containing them, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors that demonstrate sustained inhibition of the CSF / CSF1R signaling pathway with reduced toxicity. The present disclosure also provides that the CSF-1R inhibitor is one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulatory agent, each of which is optionally conjugated to a lipid. Supramolecular combinatorial therapeutics in combination with are provided. The present disclosure also provides methods for treating cancer, allergies, systemic lupus erythematosus, nephritis, chronic obstructive pulmonary disease, and abnormal macrophage function or any combination thereof. |